Brief: Nicox Outlines Future Development, Partnering Plans For NCX 470 In Glaucoma
07/11/2022 06:34
Nov 7 (Reuters) - Nicox SA NCOX.PA :
* NICOX OUTLINES FUTURE DEVELOPMENT AND PARTNERING PLANS FOR
NCX
470 IN GLAUCOMA
* OUTCOME OF MONT BLANC PHASE 3 TRIAL SUGGESTS POTENTIAL
COMMERCIAL OPPORTUNITY OF NCX 470 IN U.S. AS NOVEL ALTERNATIVE
TREATMENT FOR INTRAOCULAR PRESSURE LOWERING
* INTENTION TO HARNESS VALUE OF NCX 470 THROUGHTHE RIGHT
COMMERCIAL PARTNERSHIPS IN UNITED STATES AND JAPAN
* PLANS TO GENERATE CLINICAL DATA AIMING TO DEMONSTRATE
POTENTIAL
RETINAL BENEFITS OF NCX 470 IN ORDER TO ADD SIGNIFICANT
THERAPEUTIC VALUE TO PRODUCT PROFILE IN GLAUCOMA
Source text for Eikon: ID:nGNE30jBsm
Further company coverage: NCOX.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))